CEPI Funds Moderna, Oxford/SII, IAVI with Over $60M for Ebola Vaccine

The Coalition for Epidemic Preparedness Innovations (CEPI), a global health organization, has announced a significant funding commitment totaling over $60 million to accelerate the development of vaccines against the Bundibugyo ebolavirus (BDBV) strain. This critical funding is being allocated to three key groups: Moderna, the University of Oxford in partnership with the Serum Institute of India (SII), and the International AIDS Vaccine Initiative (IAVI). The urgency for these vaccine development efforts stems from an ongoing and rapidly spreading Ebola Bundibugyo outbreak in the eastern Democratic Republic of Congo (DRC) and neighboring Uganda. The current outbreak has led to 282 confirmed cases and 42 deaths in Congo, with an additional nine cases and one death reported in Uganda. Both the World Health Organization (WHO) and the Africa Centres for Disease Control and Prevention (Africa CDC) have declared the outbreak a Public Health Emergency of International Concern (PHEIC) and a Public Health Emergency of Continental Security (PHECS) respectively, highlighting the severe public health threat and the need for immediate, coordinated action. There are currently no approved vaccines or treatments specifically for the Bundibugyo strain of Ebola, making these development efforts paramount. CEPI's funding breakdown includes a substantial commitment of up to $50 million to Moderna. This allocation will support preclinical development and early clinical testing of Moderna's investigational Ebola Bundibugyo vaccine candidate. The funding is also intended to facilitate manufacturing processes and enable progression to later-stage trials, provided that early data demonstrate positive outcomes. Moderna's CEO, Stephane Bancel, indicated that the company has already achieved promising results in preclinical models for Ebola, and their goal is to create a vaccine that not only prevents the disease but also offers a simplified dosing strategy. Another significant portion of the funding, up to $8.6 million, is designated for a vaccine candidate developed by the University of Oxford. Crucially, this vaccine will be manufactured by the Serum Institute of India (SII), a highly reputable vaccine producer. This collaboration is particularly relevant for an Indian audience, underscoring India's role in global health initiatives and vaccine manufacturing. The Oxford vaccine uses the ChAdOx1 platform, which was also utilized for the Oxford/AstraZeneca COVID-19 vaccine, and aims to be ready for trials within approximately six weeks. CEPI's existing strategic partnership with the University of Oxford and SII's participation in CEPI's Vaccine Manufacturing Facility Network underpin this collaboration. Finally, CEPI has committed an initial $3.2 million to the International AIDS Vaccine Initiative (IAVI) for their Ebola Bundibugyo vaccine candidate. IAVI's candidate is a single-dose vaccine leveraging the same technology as Merck's approved Ervebo vaccine, which targets the Ebola Zaire strain. It has shown survival benefits in animal studies. Richard Hatchett, the head of CEPI, emphasized the critical need for speed in combating this deadly disease, noting that it might be possible to get vaccines ready for trials within a couple of months. However, he also cautioned about the unpredictable nature of vaccine development and the complexities posed by the challenging security situation in eastern Congo, which could complicate clinical trials. Beyond CEPI's direct vaccine development funding, other global health organizations have also stepped up their support for the Ebola response. Gavi, the Vaccine Alliance, has committed up to $50 million through its First Response Fund, with up to $40 million dedicated to accelerating vaccine access and $10 million for outbreak response. The World Bank's Pandemic Fund separately announced grants of up to $220.6 million to address critical response gaps in the Ebola outbreak. The Bill & Melinda Gates Foundation also committed an initial $15 million in emergency funding to support the response, distributed among Africa CDC, WHO AFRO, and WHO Headquarters for regional coordination, operational support, and procurement of critical commodities. This concerted global effort underscores the severe nature of the Ebola Bundibugyo outbreak and the collaborative international response to develop effective preventative measures. The involvement of the Serum Institute of India highlights the country's pivotal role in global vaccine production and public health security.

Frequently Asked Questions

Read Full Story on Quick Digest